Samples

Revenue segments as reported by the company.

Test revenue

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Change in fair value of contingent consideration

Asset impairment

Restructuring

Gain on sale of RUO kit assets

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Invitae

Invitae Corp. engages in the provision of genetic information into mainstream medical practice. It includes comprehensive panels for hereditary conditions in cancer, cardiology, neurology, pediatric, and rare diseases. The company was founded by Randal W. Scott and Sean E. George on January 13, 2010 and is headquartered in San Francisco, CA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Invitae reports strong Q4 earnings, eyes growth amid challenges

Invitae's Q4 2022 performance showcased revenue growth, improved margins, and reduced cash burn, positioning the company for sustainable growth.
Strategic investments in key growth areas and a focus on customer experience and profitability underpin Invitae's vision for the future.
Addressing supply chain challenges while seizing opportunities for expansion and innovation will be critical for Invitae's continued success.

Invitae (NVTA) reports robust Q1 earnings and advances in PCM technology

Invitae's Q1 2023 earnings call highlighted strong financial performance, operational strengths, and strategic advancements in PCM technology.
The company's focus on growth, margin expansion, and debt management underscores a path towards sustainable profitability.
While facing challenges in reimbursement dynamics and competitive landscape, Invitae remains poised to capitalize on growth opportunities.

Invitae reports Q2 revenue growth, adjusts guidance amid challenges

Invitae shows progress towards profitability with improved margins and reduced cash burn.
Challenges in hereditary cancer revenue and PGX exit impact revenue guidance.
Focus on expanding customer base, improving reimbursement, and reducing cash burn.
Continuous investment in products for future growth and competitiveness.

Invitae reports robust Q3 earnings, addresses financial concerns proactively

Invitae's Q3 2023 performance was strong, with revenue growth and margin expansion. The company faces challenges in capital structure and insurance payments but is actively addressing them. Opportunities lie in revenue growth, operational improvements, and expanding genetic testing services.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Invitae is a genetic information company whose mission is to bring genetic information into routine medical practice to improve the quality of healthcare for billions of people.  Specializing in genetic diagnostics for hereditary disorders, Invitae is aggregating the world’s genetic tests into a single service with better quality, faster turnaround time, and a lower price than most single-gene diagnostic tests today.  What’s our plan? It takes three steps:  --Make genetic testing more affordable and accessible than ever before. --Build a secure and trusted genome management infrastructure. --Design a new global community for sharing genetic information to advance science and medicine.  Today, we are reinventing genetic testing by lowering the barriers for clinicians and patients to obtain diagnostic genetic information. Together we can improve healthcare for billions of people.

Source: Chepko Danil Vitalevich / Shutterstock.com Invitae (NYSE: NVTA ) stock closed higher by 238% yesterday after the company reported second-quarter earnings. Today, though, NVTA stock is coming back down to earth, declining by more than 45%.

Cathie Wood Is Buying Up Red-Hot Invitae (NVTA) Stock

Invitae Corp. (NVDA) is a leading genomics testing company which was founded in 2010. Its stock price followed the standard Covid-19 boom and bust cycle alongside many peers in 2020 and 2021, which had nothing to do with the underlying company and should thus be discarded from consideration.

Invitae: A Huge Genomics Opportunity

Helbiz

T2 Biosystems

Here's what you need to know about trading penny stocks on August 11th The post Popular Penny Stocks to Watch as the Bear Market Ends appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Popular Penny Stocks to Watch as the Bear Market Ends

The stock price of Invitae (NVTA) skyrocketed 278.51% in the previous trading session. This is why.

Invitae (NVTA) Stock: Why It Skyrocketed 278.51% Yesterday

The company provided an encouraging Q2 update.

Why Invitae Stock Is Skyrocketing Today

Invitae Corp (NYSE:NVTA ) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Hoki Luk - Head, IR Kenneth Knight - President, CEO & Director Roxi Wen - CFO Conference Call Participants Yuko Oku - Morgan Stanley Puneet Souda - SVB Securities Griffin Soriano - William Blair & Company Daniel Brennan - Cowen and Company Bruce Jackson - The Benchmark Company David Westenberg - Piper Sandler & Co. David Delahunt - Goldman Sachs Group Operator Good afternoon, and thank you for attending today's Invitae 2022 Second Quarter Results Call. My name is Jason, and I will be the moderator for today's call.

Invitae Corp (NVTA) CEO Kenneth Knight on Q2 2022 Results - Earnings Call Transcript

— Continued to execute towards operational excellence with portfolio optimization, broad cost controls and cash management — — Recently announced realignment plan is expected to extend the company's cash runway to the end of 2024; Maintain financial guidance — Conference call and webcast today at 4:30 p.m. Eastern Time / 1:30 p.m.

Invitae Reports $136.6 Million in Revenue in Second Quarter of 2022

SAN FRANCISCO , Aug. 2, 2022 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it will report its second quarter 2022 financial results on Tuesday, August 9, 2022, and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m.

Invitae to Announce Second Quarter 2022 Financial Results on Tuesday, August 9, 2022

An analyst downgrades his recommendation on the stock, making a brutal cut to his price target while doing so.

Why Invitae Health Stock Plummeted This Week

Invitae (NVTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Invitae (NVTA) Report Negative Q2 Earnings? What You Should Know

The genetic-testing company had a lot of news that investors didn't like.

Why Invitae Stock Crashed Today

Invitae (NVTA) stock is falling on Tuesday after the biotechnology company revealed plans to cut costs as part of a strategic realignment. The post Invitae (NVTA) Stock Falls 12% on Cost-Cutting Plan appeared first on InvestorPlace.

Invitae (NVTA) Stock Falls 12% on Cost-Cutting Plan

Invitae Corp (NYSE: NVTA) plans to focus its resources on higher-margin and higher-growth businesses, including oncology, women's health, rare disease, and pharmacogenomics.  It will also continue to integrate key digital health technologies and services.

Invitae Outlines Cost Saving Plan, Leadership Transition

Company announces actions to lower near-term cash burn. Revenue growth targets come in well below expectations.

Invitae: Major Restructuring Will Likely Kill Growth Story

—   Exiting non-core businesses and geographies to prioritize higher-margin business initiatives — —   Expects to deliver approximately $326 million in non-GAAP annualized cost savings in 2023 — —   Provides preliminary revenue and gross margin ranges for the second quarter of 2022; amends full-year 2022 financial guidance — — Conference call and webcast today at 5:00 p.m. Eastern Time / 2:00 p.m.

Invitae Announces Strategic Business Realignment to Accelerate Its Path to Positive Cash Flow and Realize Full Potential of Industry-Leading Genetics Testing Platform

—   COO Kenneth D. Knight named CEO succeeding Sean George; Dr. George to continue as member of Board of Directors — —   Co-Founder and former CEO Randy Scott returns as chairman — —   Current chairman Eric Aguiar to serve as lead independent director — SAN FRANCISCO , July 18, 2022 /PRNewswire/ --  Invitae (NYSE: NVTA), a leading medical genetics company, today announced executive leadership and Board changes to help ensure the company realizes the full potential of its industry-leading genetics testing platform and delivers tangible and sustainable value for stockholders.

Invitae Announces Leadership Transition

Invitae (NVTA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Bears are Losing Control Over Invitae (NVTA), Here's Why It's a 'Buy' Now

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- #CRO--Worldwide Clinical Trials announces partnership with Invitae to improve global research with enhanced data insights for rare disease studies.

Worldwide Clinical Trials Enters Into a Strategic Collaboration With Invitae to Accelerate Clinical Trials for Rare Disease Patients

Invitae's problems make the stock a speculative lottery ticket.

Bear Market or Not, You Shouldn't Inherit This Stock's Problems

Benitec Biopharma Limited Sponsored ADR

Clovis Oncology

Alaunos Therapeutics

Biotech penny stocks to watch right now. The post Penny Stocks To Buy Now?

Penny Stocks To Buy Now? 4 Biotech Stocks To Watch Before July 2022

Invitae, a next-gen healthcare/biotech company, has seen its stock getting hammered due to strong worries about a looming bankruptcy due to reckless cash burn. However, in the last few quarters, the company has started to shift from growth-at-all-costs to focusing on reducing the cash burn, with a $100M annualized reduction in Q1 alone.

Invitae: Coming Out Of The Cash Burn

Investors are taking a new, bearish analyst view on the company to heart.

Why Invitae Stock Plummeted by 15% Today

Amyris

Lovesac Company

Find out why the pros think these stocks could gain 200% or better.

3 Stocks Wall Street Thinks Could Triple Your Money or Better

SAN FRANCISCO , May 27, 2022 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will participate in the following investor conferences: 42nd Annual William Blair Growth Stock Conference - Formal presentation on Tuesday, June 7, 2022, at 8:40 a.m. Central Time in Chicago.

Invitae to Present at Upcoming Investor Conferences

- New data to be presented by Invitae at 2022 ASCO Annual Meeting show importance of genetic testing for all cancer patients - SAN FRANCISCO , May 26, 2022 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced eight studies to be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago from June 3-7, 2022. While the research covers a variety of cancer types, stages and patient demographics, all of the data underscore the importance of universal genetic testing to improve health outcomes for all cancer patients.

News for Invitae Stock (NVTA)